



Krazati in India

The CDSCO named-patient coordination pathway — indicative 2026

ONCOLOGY · KRAS G12C NSCLC

The clinical situation

Krazati (adagrasib) is an oral, selective covalent inhibitor of KRAS G12C, an oncogenic driver mutation previously considered undruggable. Manufactured by Mirati Therapeutics (now Bristol Myers Squibb). Eligibility anchors to a confirmed KRAS G12C alteration on validated NGS (tissue or plasma), prior systemic therapy, and a performance status consistent with FDA labelling. Dosing is typically 600 mg orally twice daily, with monitoring for QTc, hepatic panel, and GI tolerability.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating medical oncologist confirms KRAS G12C on NGS, documents prior-therapy sequence, and writes the rationale letter.
- 2 Molecular-testing confirmation.** Tissue or plasma NGS report documenting KRAS G12C — the gating evidence for the file.
- 3 CDSCO personal-use application.** Physician or importing pharmacy files dossier: rationale, patient reference, dosing plan, chain-of-custody.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Arrival & initiation.** The importer of record receives Krazati; your oncology team dispenses and manages adverse events per FDA labelling.

Indicative economics

Reference US cash-pay range: USD 19,000–22,000 per 30-day supply (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and CDSCO review, keyed to the KRAS G12C rationale. **Logistics.** Temperature-controlled shipment with importer-of-record handling. **Concierge case lead.** Named point of contact for family and oncology team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Krazati × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/krazati-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team